EGFR and neoplasm: Gene knockdown and antitumoral essays using an intracranial glioma model demonstrated that FA-PAMAM vehicles provided greater inhibition of EGFR expression than PAMAM carriers and passive ASO delivery, which led to substantial tumour suppression two weeks after tumour implantation and prolonged survival.